2011 Scrip 100: Oncology trials
This article was originally published in Scrip
Between 1 October 2009 and 30 September 2010, there were 428 new Phase II to Phase III clinical trials initiated by industry sponsors in the oncology arena. Non-small cell lung cancer was the clear disease focus, accounting for 11% of these new trials. Breast cancer, multiple haematological cancers, non-Hodgkin's lymphoma and colorectal cancer rounded out the top five disease areas, together accounting for 35% (147) of the total trials initiated.
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.